Powered by

Karius Secures $165 Million In Series B Funding Led By SoftBank Vision Fund 2; Karius will expand access to its proprietary microbial cell-free DNA technology to help doctors diagnose infectious diseases, broaden clinical development, and accelerate techn

Feb 24, 2020 - PR Newswire
Investments

PR Newswire

Karius, the world leader in liquid biopsy for infectious diseases, secured $165 million in a new funding round led by SoftBank Vision Fund 21, with additional participation from General Catalyst, HBM Healthcare Investments, and existing investors Khosla Ventures and LightSpeed Venture Partners. Karius pioneered the discovery and application of microbial cell-free DNA, enabling non-invasive detection of pathogens throughout the body with its KariusĀ® Test. Today, the Karius Test...